Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.75 USD
+0.09 (5.42%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RPHM 1.75 +0.09(5.42%)
Will RPHM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RPHM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPHM
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
RPHM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RPHM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Reneo Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
Mitchell Kapoor’s Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline Potential
RPHM Alert: Monsey Firm of Wohl & Fruchter Investigating Proposed Merger of Reneo Pharmaceuticals With OnKure
Reneo Pharmaceuticals Announces Merger and Strategic PIPE Investment